These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 30686720)

  • 1. For the greatest impact, end caps on PrEP access now.
    The Lancet Hiv
    Lancet HIV; 2019 Feb; 6(2):e67. PubMed ID: 30686720
    [No Abstract]   [Full Text] [Related]  

  • 2. Better late than never: PrEP in England.
    The Lancet Hiv
    Lancet HIV; 2017 Jan; 4(1):e1. PubMed ID: 28007341
    [No Abstract]   [Full Text] [Related]  

  • 3. PrEP: why are we waiting?
    Lancet HIV
    Lancet HIV; 2015 Oct; 2(10):e401. PubMed ID: 26423641
    [No Abstract]   [Full Text] [Related]  

  • 4. Highlights of HIVR4P 2018.
    Zuccala E
    Lancet HIV; 2018 Dec; 5(12):e683. PubMed ID: 30527326
    [No Abstract]   [Full Text] [Related]  

  • 5. Defining the HIV pre-exposure prophylaxis care continuum.
    Nunn AS; Brinkley-Rubinstein L; Oldenburg CE; Mayer KH; Mimiaga M; Patel R; Chan PA
    AIDS; 2017 Mar; 31(5):731-734. PubMed ID: 28060019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eliminating the HIV epidemic: the US government can make preexposure prophylaxis affordable now.
    Faustino E; Fielding J; Teutsch S
    AIDS; 2019 Oct; 33(12):1951-1952. PubMed ID: 31490216
    [No Abstract]   [Full Text] [Related]  

  • 7. Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries.
    Hoornenborg E; Krakower DS; Prins M; Mayer KH
    AIDS; 2017 Oct; 31(16):2179-2191. PubMed ID: 28991023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PrEP: why we are waiting.
    Jansen MP; Tromp N; Baltussen R
    Lancet HIV; 2016 Jan; 3(1):e11-2. PubMed ID: 26762986
    [No Abstract]   [Full Text] [Related]  

  • 9. Race and the Public Health Impact Potential of Pre-Exposure Prophylaxis in the United States.
    Schneider JA; Bouris A; Smith DK
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):e30-2. PubMed ID: 25950209
    [No Abstract]   [Full Text] [Related]  

  • 10. Users of a National Directory of PrEP Service Providers: Beliefs, Self-Efficacy, and Progress Toward Prescription.
    Bratcher A; Schlueter Wirtz S; Siegler AJ
    J Acquir Immune Defic Syndr; 2018 Aug; 78(4):e28-e30. PubMed ID: 29672350
    [No Abstract]   [Full Text] [Related]  

  • 11. Pre-exposure prophylaxis access in federally qualified health centers across 11 United States metropolitan statistical areas.
    Tookes H; Yao K; Chueng T; Butts S; Karsner R; Duque M; Cardenas G; Feaster DJ; Doblecki-Lewis S
    Int J STD AIDS; 2019 Sep; 30(10):978-984. PubMed ID: 31284842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
    Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
    HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decline in new HIV diagnoses among MSM in Melbourne.
    Chow EPF; Medland NA; Denham I; Wright EJ; Fairley CK
    Lancet HIV; 2018 Sep; 5(9):e479-e481. PubMed ID: 30215345
    [No Abstract]   [Full Text] [Related]  

  • 14. Authors' Reply: Race and the Public Health Impact Potential of Pre-Exposure Prophylaxis in the United States.
    Cohen SE; Vittinghoff E; Doblecki-Lewis S; Coleman M; Bacon O; Elion R; Kolber MA; Buchbinder S; Liu AY
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):e33-5. PubMed ID: 26049284
    [No Abstract]   [Full Text] [Related]  

  • 15. Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation.
    Landovitz RJ
    Top Antivir Med; 2015; 23(2):85-90. PubMed ID: 26200708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs.
    Biello KB; Bazzi AR; Mimiaga MJ; Biancarelli DL; Edeza A; Salhaney P; Childs E; Drainoni ML
    Harm Reduct J; 2018 Nov; 15(1):55. PubMed ID: 30419926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical issues in trials of preexposure prophylaxis.
    Dunn DT; Glidden DV
    Curr Opin HIV AIDS; 2016 Jan; 11(1):116-21. PubMed ID: 26545264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention Strategies Against HIV Transmission: A Proactive Approach.
    Carrion AJ; Miles JD; Mosley JF; Smith LL; Prather AS; Gurley MM; Phan LD; Everton EC
    J Pharm Pract; 2018 Feb; 31(1):82-90. PubMed ID: 29278971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of healthcare providers in the roll out of preexposure prophylaxis.
    Krakower DS; Mayer KH
    Curr Opin HIV AIDS; 2016 Jan; 11(1):41-8. PubMed ID: 26417953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing and Assessing the Feasibility of a Home-based Preexposure Prophylaxis Monitoring and Support Program.
    Siegler AJ; Mayer KH; Liu AY; Patel RR; Ahlschlager LM; Kraft CS; Fish R; Wiatrek SE; Sullivan PS
    Clin Infect Dis; 2019 Jan; 68(3):501-504. PubMed ID: 29982304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.